


TransMedRi Workshop in Biostatistics:

Critical evaluation of statistical analysis in scientific paper

Power analysis in research

Mladen Petrovečki



Rijeka University School of Medicine Department of Medical Informatics

Statistics in health research

Statistics for career training: Scientists receive the highest priority for the requested EU contribution. It is important to note that funding limits will be applied as eligibility criteria. Proposals that do not respect this limit will be considered ineligible.

- Statistics in health research:** Appropriate study design, data processing and statistical analysis of results are important for the quality and efficiency of the science and reliability of conclusions, and hence also ethically. So, whenever applicable, the proposal should explain them. This may for example include description of experimental plan and data gathering, method for uncertainty or measurement error estimation, statistical analysis of data and methods of inference (e.g. statistical tests and p-values to be used, accounting for multiple comparisons or small sample size, dealing with missing or noisy data), statistical power analysis, and estimate (justification) of the number of needed animals or human subjects. If these are not applicable or not justified, the proposal should briefly explain it.
- Innovative clinical trials¹ to verify safety and efficacy:** Specific actions under clinical trials will have a major European added value in translating research into clinical practice, increasing therapeutic options for patients, stimulating the implementation of best

- Proposed priorities for innovative health research 2012**
(Working document – not legally binding; Indicative publication date for all documents including the final work programme is 20 July 2011. All related documents will then be accessible via <http://cordis.europa.eu/fp7/ef/index.cfm>)



Rijeka University School of Medicine Department of Medical Informatics

Journal article

during the 6 months of follow-up. Data entry was done by administrative assistants, blinded to the assigned treatment.

Statistical analysis
 Based on an α of 5% and 80% power, we calculated that 250 patients were needed in each treatment arm to detect a clinically relevant reduction in the incidence of zoster-associated pain 1 month after the onset of the zoster rash from 12% to 5%. Although earlier studies showed an incidence of postherpetic neuralgia of 9–34% when using standard treatment, we used a more conservative incidence to be expected in our control group based on data from a pilot study.¹⁶ Allowing for 10% loss of follow-up, the required number of study patients was 550. Analyses were carried out with an intention-to-treat approach. The presence of pain (at the different time points) in the two groups was compared by calculating


- Lancet 2006; 367: 219–24**
(Albert) M van Wijck, Wim Opstelten, Karol G M Moons, Gerrit A van Esen, Robert J Stolker, Cornelis J Kalkman, Theo J M Verheij. The PINE study of epidural steroids and local anesthetics to prevent postherpetic neuralgia: a randomized controlled trial



Rijeka University School of Medicine Department of Medical Informatics

Statistical power


- ...the ability of a test statistic to detect a specified alternative hypothesis or difference of a specified size when alternative hypothesis is true*
 - B. Dawson & R.G. Trapp
 - Basic & clinical biostatistics, 4th ed., Lange Medical Books/McGraw-Hill, New York-Toronto, 2004
- ...is a measure of the likelihood that a researcher will find statistical significance in a sample if the effect exists in the full population*
 - M.L. McHugh
 - Power analysis in research, Biochemia Medica 2008;18(3):263–74
 - <http://www.biochemia-medica.com/content/18-3-259-402>



Rijeka University School of Medicine Department of Medical Informatics

Statistical power


- ...ability of a study to detect an actual effect or difference*
 - B. Dawson & R.G. Trapp
 - Basic & clinical biostatistics, 4th ed., Lange Medical Books/McGraw-Hill, New York-Toronto, 2004



Rijeka University School of Medicine Department of Medical Informatics

Hypothesis

- Null hypothesis
 - H_0 – no difference
- Alternate hypothesis
 - H_1 – difference exists
- Only one can be **truthful**
 - Only one can be **accepted**
 - Other will be **rejected**



Rijeka University School of Medicine Department of Medical Informatics

Hypothesis testing

Reality		Conclusion from hypothesis test
No difference (H_0)	Difference (H_1)	
type I error (α error)	correct power	difference exists (reject H_0)
correct	type II error (β error)	no difference (accept H_0)



Rijeka University School of Medicine Department of Medical Informatics



Hypothesis testing: No difference



Rijeka University School of Medicine Department of Medical Informatics



Hypothesis testing vs. diagnostic testing

- Type I error → FP rate
 - significance found with no significance in real
- Type II error → FN rate
 - significance not found for significance in real
- Test power → Sensitivity
 - detecting significance when result is significant



Rijeka University School of Medicine Department of Medical Informatics



Statistical power


- Value
 - 0 – 1; ≥ 0.8 mostly suggested
- Factors
 - primary
 - size of the effect ← clinical significance
 - variability of observations
 - level of significance ← statistical significance
 - sample size
 - secondary
 - statistical test



Rijeka University School of Medicine Department of Medical Informatics



Power curve



Rijeka University School of Medicine Department of Medical Informatics



Factors of statistical power

1. Size of the effect (clinical significance)
2. Variability of observations
3. Level of significance (statistical significance)
4. Sample size
5. Statistical test

Representative sample!



Rijeka University School of Medicine Department of Medical Informatics



1. Effect size

- Magnitude of the effect, smallest effect of interest
- Smallest size of the difference between groups
 - e.g. I, humans, proportion with *Helicobacter pylori*
 - sample: 65/100 = 65%
 - control: 24/30 = 80%
 - effect size: 15%
 - e.g. II, glucose, human subject
 - sample: 5±1 mmol/L
 - control: 4.5±1 mmol/L
 - effect size: 0.5 mmol/L
- ↑ effect = ↑ power



Rijeka University School of Medicine Department of Medical Informatics



Effect size

- ↑ effect = ↑ power



Rijeka University School of Medicine Department of Medical Informatics



Determining the effect

- Prior studies published
- Estimation of minimal effect
 - from pilot study
 - set by definition
 - peer review before starting the study
 - e.g., study protocol evaluation



Rijeka University School of Medicine Department of Medical Informatics



Effect size of association

- What is the size of effect?
- Measuring: correlation
 - numeric variables → Pearson's r
 - ordinal variables → Spearman's r
 - t-test → point biserial r
 - ANOVA → η^2 (eta-squared)
 - etc.
- Importance: for studies with huge N
- r^2 → variance explained



Rijeka University School of Medicine Department of Medical Informatics



2. Variability (numerical data)

- ↑ variability = ↓ power



Rijeka University School of Medicine Department of Medical Informatics



3. Significance level

- Notation, according to testing:
 - before – α
 - after – P
- ↓ α = ↑ power
- $\alpha < 0.05$
- $\alpha < 0.01$
- $\alpha < 0.001$



Rijeka University School of Medicine Department of Medical Informatics



4. Sample size

- **Must be planned** for the study
- \uparrow sample size = \uparrow power
 - sample **must** be representative
 - population study \rightarrow power = 1
- What is appropriate sample size?
 - answer: power analysis
 - variables:
 - level of significance (α)
 - power ($1-\beta$)
 - effect size (E)
 - variability (v)



Rijeka University School of Medicine Department of Medical Informatics



Power analysis

- Sample size estimation
 - $N_{\text{sample}} \sim \alpha, \beta \& E, v$
- Always **before** beginning of the study
- Sample size
 - the smallest possible (ethics)
 - methodology
 - occasionally
 - general & quick formulae
 - tables
 - nomogram
 - software

Lehr's equation for unpaired t-test with $\alpha=0.05$ and 80% power
 $N = 16/SD^2$
 SD – standardized difference
 SD = the smallest difference in means still clinically important / assumed equal standard deviation



Rijeka University School of Medicine Department of Medical Informatics



Power analysis

- Sample size estimation
 - $N_{\text{sample}} \sim \alpha, \beta \& E, v$
- Always **before** beginning of the study
- Sample size
 - the smallest possible (ethics)
 - methodology
 - occasionally
 - general & quick formulae
 - tables
 - nomogram
 - software

Sample size table for correlation (quick table)

This is the truncated version of the full table (next section), for quick references to sample size required to establish a correlation coefficient (r) of a particular value, in the most common situation where power=0.8 and alpha (α)=0.05

<http://www.stattools.net/>

• r = correlation coefficient
 • ss = sample size

r(p)	ss	r(p)	ss	r(p)	ss	r(p)	ss
0.02	15455	0.22	126	0.42	33	0.62	15
0.04	3862	0.24	106	0.44	30	0.64	14
0.06	1716	0.26	90	0.46	28	0.66	13
0.08	964	0.28	77	0.48	25	0.68	12
0.10	617	0.30	67	0.50	23	0.70	11
0.12	428	0.32	59	0.52	21	0.72	10
0.14	314	0.34	52	0.54	20	0.74	10
0.16	240	0.36	46	0.56	18	0.76	9
0.18	189	0.38	41	0.58	17	0.78	9
0.20	153	0.40	37	0.60	16	0.80	8




Rijeka University School of Medicine Department of Medical Informatics



Power analysis

- Sample size estimation
 - $N_{\text{sample}} \sim \alpha, \beta \& E, v$
- Always **before** beginning of the study
- Sample size
 - the smallest possible (ethics)
 - methodology
 - occasionally
 - general & quick formulae
 - tables
 - nomogram
 - software



Rijeka University School of Medicine Department of Medical Informatics



Power analysis

- Sample size estimation
 - $N_{\text{sample}} \sim \alpha, \beta \& E, v$
- Always **before** beginning of the study
- Sample size
 - the smallest possible (ethics)
 - methodology
 - occasionally
 - general & quick formulae
 - tables
 - nomogram
 - software

Sampling: single mean

Type I error - Alpha: 0.20 0.05 0.01

Type II error - Beta: 0.20 0.05 0.01

Input:
 Mean:
 Standard deviation:
 Null Hypothesis value:

Result:
 Minimal required sample size:

Buttons: Help, Calculate, Exit



Rijeka University School of Medicine Department of Medical Informatics



Sample size estimation, examples

1. humans, proportion with *Helicobacter pylori*
 - sample: 65/100 = 65%
 - control: 24/30 = 80%
 - effect size: 15%
2. glucose, human subject
 - sample: 5±1 mmol/L
 - control: 4.5±1 mmol/L
 - effect size: 0.5 mmol/L




Rijeka University School of Medicine Department of Medical Informatics



Sample size estimation, examples

1. humans, proportion with *Helicobacter pylori*

- sample: $65/100 = 65\%$
- control: $24/30 = 80\%$
- effect size: 15%



Rijeka University School of Medicine Department of Medical Informatics

Sample size estimation, examples

1. humans, proportion with *Helicobacter pylori*

- sample: $65/100 = 65\%$
- control: $24/30 = 80\%$
- effect size: 15%


- <http://www.stat.ubc.ca/~rollin/stats/ssize/b2.html>

Rijeka University School of Medicine Department of Medical Informatics

Sample size estimation, examples

2. glucose, human subject

- sample: 5 ± 1 mmol/L
- control: 4.5 ± 1 mmol/L
- effect size: 0.5 mmol/L



Rijeka University School of Medicine Department of Medical Informatics

Sample size estimation, examples

2. glucose, human subject

- sample: 5 ± 1 mmol/L
- control: 4.5 ± 1 mmol/L
- effect size: 0.5 mmol/L

- <http://www.stat.ubc.ca/~rollin/stats/ssize/n2.html>
- <http://www.stat.uiowa.edu/~rlenth/Power/>

Rijeka University School of Medicine Department of Medical Informatics

Sample size adjustment

- losses to follow up
 - drop-out rate, d
 - $N_{\text{adjusted}} = N \cdot 100/(100-d)$
- independent groups of different sizes
- final-stage critical value to protect the overall type-I error rate

Rijeka University School of Medicine Department of Medical Informatics

Important!

- <http://www.consort-statement.org/home/>
Consolidated Standards of Reporting Trials, encompasses various initiatives developed by the CONSORT Group to alleviate the problems arising from inadequate reporting of randomized controlled trials (RCTs)

Rijeka University School of Medicine Department of Medical Informatics

5. Statistical test

- Secondary factor
- Each statistical tests ← power level
 - parametric > non-parametric
 - chi-squared test > Fisher exact probability test
 - etc.
- Most important: **appropriate statistical test**
 - nominal/ordinal/numeric variables
 - data distribution
 - sample size
 - etc.



Rijeka University School of Medicine Department of Medical Informatics



Conclusion

- Power of the study
 1. Size of the effect (**clinical significance**)
 2. Variability of observations
 3. Level of significance (**statistical significance**)
 4. Sample size
 5. Statistical test



Rijeka University School of Medicine Department of Medical Informatics

